Skip to main content

Turner Syndrome

7
Pipeline Programs
10
Companies
7
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
4
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Novo Nordisk
VAGIFEMApproved
estradiol
Novo Nordisk
Estrogen [EPC]vaginal1999
3M Part D

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Prevail Therapeutics
5 programs
3
1
HumatropePhase 4
17 beta estradiolPhase 3
SomatropinPhase 3
SomatropinPhase 3
Turner Syndrome Prenatal Diagnosis StudyN/A
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
estradiolPHASE_41 trial
Active Trials
NCT00134745Completed43Est. Mar 2013
Genentech
GenentechCA - Oceanside
1 program
1
17 B estradiol orallyPhase 41 trial
Active Trials
NCT00837616Completed41Est. Dec 2012
Nielsen BioSciences
Nielsen BioSciencesCA - San Diego
1 program
1
estradiolPhase 4
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
Turner Syndrome Prenatal Diagnosis StudyN/A1 trial
17 beta estradiolPHASE_31 trial
Active Trials
NCT01668251Unknown60Est. Jan 2017
NCT00140998Completed16Est. Jun 2004
Lundbeck
LundbeckDenmark - Copenhagen
1 program
X-chromosome Inactivation, Epigenetics and the TranscriptomeN/A1 trial
Active Trials
NCT01678261Completed110Est. Jan 2016
Pfizer
PfizerNEW YORK, NY
1 program
somatotropinN/A1 trial
Active Trials
NCT01367834Completed17Est. May 2014
Ipsen
IpsenChina - Tianjin
1 program
SomatropinPHASE_31 trial
Active Trials
NCT00234533Completed251Est. Jul 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Genentech17 B estradiol orally
Novo Nordiskestradiol
IpsenSomatropin
Eli Lilly and Company17 beta estradiol
LundbeckX-chromosome Inactivation, Epigenetics and the Transcriptome
Pfizersomatotropin
Eli Lilly and CompanyTurner Syndrome Prenatal Diagnosis Study

Clinical Trials (7)

Total enrollment: 538 patients across 7 trials

NCT00837616Genentech17 B estradiol orally

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

Start: Jan 2009Est. completion: Dec 201241 patients
Phase 4Completed
NCT00134745Novo Nordiskestradiol

Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome

Start: Jun 2005Est. completion: Mar 201343 patients
Phase 4Completed
NCT00234533IpsenSomatropin

Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq

Start: Jun 2004Est. completion: Jul 2008251 patients
Phase 3Completed
NCT00140998Eli Lilly and Company17 beta estradiol

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

Start: Jan 2001Est. completion: Jun 200416 patients
Phase 3Completed
NCT01678261LundbeckX-chromosome Inactivation, Epigenetics and the Transcriptome

X-chromosome Inactivation, Epigenetics and the Transcriptome

Start: Sep 2012Est. completion: Jan 2016110 patients
N/ACompleted
NCT01367834Pfizersomatotropin

Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome

Start: May 2010Est. completion: May 201417 patients
N/ACompleted
NCT01668251Eli Lilly and CompanyTurner Syndrome Prenatal Diagnosis Study

Turner Syndrome Prenatal Diagnosis Study

Start: Jan 2006Est. completion: Jan 201760 patients
N/AUnknown

Related Jobs

Associate Director, Program Safety Lead - Job ID: 1908

Ascendis PharmaAscendis Pharma
Princeton, New Jersey, United States (Hybrid)
1mo ago
$458K - $510K/yr

Product Manager Endocrinology (f/m/d)

Ascendis PharmaAscendis Pharma
Munich, Bavaria (Hybrid)
1mo ago

Talent Pool

Ascendis PharmaAscendis Pharma
5y ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.